QIAGEN Adds Promising New Biomarker to Pipeline of Personalized Healthcare Assays to Improve Diagnosis of Blood Disorders - Seite 2

Rotor-Gene Q MDx, which is part of our industry-leading QIAsymphony
family of automated platforms. CALR and JAK2 could also be promising
targets for companion diagnostics as future drug candidates for these
blood disorders may be linked to these biomarkers."

Giulio Superti-Furga, Scientific Director of CeMM, said: "We
estimate that up to 3 million people worldwide suffer from
myeloproliferative neoplasms, and discovery of the CALR mutation by
our CeMM and Medical University of Vienna research teams is a very
important finding for the benefit of these patients. We are pleased
to license the CALR biomarker to QIAGEN. The development of a
standardized test will enable physicians to provide improved patient
care. At the same time, our researchers will continue to advance the
understanding of these diseases and to focus on developing novel
treatment options. CeMM is constantly investing in basic research
aimed at obtaining new insights in potential diagnostics and
therapeutics."

With the technologies licensed from CeMM, QIAGEN plans to develop
commercial kits for the detection of CALR mutations and seek
regulatory approvals for those products. These diagnostics will join
the growing portfolio of kits designed to run on the QIAsymphony
automation platform. In addition, the license from CeMM includes
potential use of the biomarker in next-generation sequencing
applications.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global
provider of Sample & Assay Technologies that are used to transform
biological materials into valuable molecular information. Sample
technologies are used to isolate and process DNA, RNA and proteins
from biological samples such as blood or tissue. Assay technologies
are then used to make these isolated biomolecules visible and ready
for interpretation. QIAGEN markets more than 500 products around the
world, selling both consumable kits and automation systems to
customers through four customer classes: Molecular Diagnostics (human
healthcare), Applied Testing (forensics, veterinary testing and food
safety), Pharma (pharmaceutical and biotechnology companies) and
Academia (life sciences research). As of December 31, 2013, QIAGEN
employed approximately 4,000 people in more than 35 locations
worldwide. Further information can be found at http://www.QIAGEN.com.

Certain of the statements contained in this news release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E